GFH375 Ph I/II (mono, pretreated PDAC): ORR 41%, DCR 97%, mPFS 5.5 mo 4-mo PFS 78%, OS 92% GemNP + HRS-4642 PhI/II (1L PDAC): ORR 63%, DCR 93% 6-mo PFS 89% By comparison, NALIRIFOX in NAPOLI-3: ORR 42%, DCR 68%, 6-mo PFS ~60% Interesting data- NALIRIFOX + KRASi next? #ESMO25

Honoured to discuss EORTC BTG 2227 LEGATO trial and to discuss issues related to postop SRS in pts with brain mets! Thanks to @EANOassociation #EANO2025 to come to Prague, Czechia @MOU_Brno

In PTEN-deficient de novo mHSPC, CAPItello-281 shows: 🔹 rPFS HR 0.81 (P=0.034) for capi + abi vs abi 🔹 Trend toward improved OS 🔹 Increasing benefit at ≥95–100% PTEN loss A step forward in PI3K/AKT-targeted therapy for prostate cancer. #ProstateCancer #ESMO25

🟢 Live from #ESMO25 | @OncoAlert @MedicalwatchHQ Surgery for Oligoprogression 👨‍⚕️ Speaker: Grant D. Stewart, MD PhD (@Cambridge_Uni) 💡 Key takeaways: ➡️ CARMENA & SURTIME confirm systemic therapy as cornerstone; CNx should be deferred or omitted in poor-risk disease. ➡️

First-line pembrolizumab-based regimens for advanced clear cell renal cell carcinoma: KEYMAKER-U03 substudy 03A #ESMO25

First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) #ESMO25

Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: The randomized phase II NESCIO trial #ESMO25

💫🌟🟢 Live from #ESMO25 @OncoAlert @MedicalwatchHQ SBRT for Oligoprogression 👨‍⚕️ Speaker: Shankar Siva, MD PhD (@_ShankarSiva) 💡 Key takeaways: ➡️ SBRT provides a non-invasive, cost-effective alternative to metastasectomy — maintaining systemic therapy continuity and

💫🌟💬 Invited discussant of LBA93 & LBA95 @OncoAlert @MedicalwatchHQ @myESMO 💡 @DrRanaMcKay, MD, FASCO synthesized both RAMPART & NESCIO highlighting key insights: ⚡ 1️⃣ Shift from adjuvant to neoadjuvant:  Perioperative immunotherapy is reshaping the management of localized

🟢 Live from #ESMO25 @OncoAlert @MedicalwatchHQ 💫🌟Oligoprogressive RCC: Opportunities for multidisciplinary involvement🌟💫 👩‍⚕️ Speaker: Cristina Suárez (@VHIO) 💡 Key insights from Dr. Suárez’s talk: ➡️ Oligometastatic & oligoprogressive RCC are biologically distinct states

LGG in pregnancy or issues related to Return to work as topics which we discussed in EANO tumor board. Education day is ongoing, welcome in Prague, @EANOassociation @MOU_Brno

Ready for #ESMO25? Presidential Sessions will be full of GU abstracts… but there are many other interesting and potentially practice-changing trials that will also be presented. Don’t miss them!

Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial - European Urology

New review on reirradiation for recurrent glioblastoma with focus on studies published during last 2 years : Current Opinion in Oncology https://t.co/EdiTFxm9RK. @MOU_Brno

It was a great honour and privilege to be part of this great event, special thanks to Professor Kucharz. https://t.co/EpNRy2tDp8

The #THOR2 trial confirms the efficacy of #Erdafitinib for patients with FGFR3/2alt-altered HR- or IR- #NMIBC. A promising step forward in personalized #BladderCancer care. #Clinicalresearch #Oncology #Genitourinary #PrecisionMedicine Full article here https://t.co/IihZami6xC

Happy to be part of the team helping to establish Croatian Oncology Research Network (CORN) - CCI4EU project with active role of @MOU_Brno

Molecular classification of nonurothelial histologic subtypes of bladder cancer

No age barrier for immunotherapy in renal cell carcinoma, but smarter prognostic tools can guide decisions. 🔗 https://t.co/K9EuaIOheJ 🔗 https://t.co/jD5NCPsUSh... #RCC #Immunotherapy #MeetURO #Oncology @urologysummit @urotoday @meeturoIT @ONCOassist

💡 CheckMate 901 – Lymph Node–Only Metastatic Urothelial Carcinoma Exploratory post hoc analysis shows that nivolumab + gemcitabine–cisplatin improves survival and deepens responses in patients with LN-only metastatic UC. 🔹 Median OS: 46.3 vs 24.9 months 🔹 Median PFS: 30.5 vs